Isracann Biosciences Inc.
Isracann Biosciences Inc. (ISCNF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ISCNF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsIsracann Biosciences Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-05-31 | $0.00B | +$0.00B | — |
| 2021-05-31 | $0.00B | +$0.00B | — |
| 2020-05-31 | $0.00B | +$0.00B | — |
| 2019-05-31 | $0.00B | -$0.00B | -100.00% |
| 2018-05-31 | $0.00B | +$0.00B | +264.88% |
| 2017-05-31 | $0.00B | +$0.00B | +72.54% |
| 2016-05-31 | $0.00B | +$0.00B | +382.72% |
| 2015-05-31 | $0.00B | +$0.00B | — |
| 2014-05-31 | $0.00B | +$0.00B | — |
| 2013-05-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Isracann Biosciences Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Isracann Biosciences Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Isracann Biosciences Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ISCNF revenue · 4 questionsISCNF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Isracann Biosciences Inc. SEC filings · GAAP · Isracann Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026